Table 2 Hazard ratios of MACE in patients receiving different 2nd-line anti-diabetic agents
Variable | Event | PYs | Rate | Crude HR (95% CI) | Adjusted HR (95% CI) | p value |
|---|---|---|---|---|---|---|
MACE | ||||||
 Met+SU users | 4512 | 155,459 | 29.0 | Ref. | Ref. | – |
 Met+AGI users | 70 | 3735 | 18.7 | 0.72 (0.57–0.92) | 0.74 (0.59–0.94) | 0.01 |
 Met+TZD users | 50 | 2814 | 17.8 | 0.68 (0.51–0.89) | 0.66 (0.50–0.88) | 0.004 |
 Met+glinide users | 141 | 5187 | 27.2 | 1.01 (0.85–1.19) | 0.89 (0.75–1.06) | 0.18 |
 Met+DPP-4I users | 2 | 194 | 10.3 | 0.52 (0.13–2.08) | 0.52 (0.13–2.10) | 0.36 |
ACS | ||||||
 Met+SU users | 693 | 163,037 | 42.5 | Ref. | Ref. | – |
 Met+AGI users | 11 | 3805 | 28.9 | 0.76 (0.42–1.39) | 0.74 (0.41–1.34) | 0.32 |
 Met+TZD users | 10 | 2851 | 35.1 | 0.91 (0.49–1.71) | 0.85 (0.45–1.59) | 0.61 |
 Met+glinide users | 14 | 5364 | 26.1 | 0.66 (0.39–1.12) | 0.60 (0.35–1.03) | 0.06 |
 Met+DPP-4I users | 0 | 194 | 0 | – | – | – |
Stroke | ||||||
 Met+SU users | 2206 | 157,529 | 140 | Ref. | Ref. | – |
 Met+AGI users | 35 | 3750 | 93.3 | 0.71 (0.51–1.00) | 0.71 (0.51–0.99) | 0.04 |
 Met+TZD users | 16 | 2833 | 56.5 | 0.43 (0.26–0.70) | 0.41 (0.25–0.67) | 0.0004 |
 Met+glinide users | 75 | 5213 | 144 | 1.07 (0.85–1.35) | 0.95 (0.75–1.20) | 0.66 |
 Met+DPP-4I users | 1 | 194 | 51.7 | 0.46 (0.07–3.30) | 0.46 (0.06–3.24) | 0.43 |
Ischemic stroke | ||||||
 Met+SU users | 1850 | 158,569 | 117 | Ref. | Ref. | – |
 Met+AGI users | 27 | 3765 | 71.7 | 0.66 (0.45–0.96) | 0.65 (0.44–0.95) | 0.02 |
 Met+TZD users | 11 | 2845 | 38.7 | 0.35 (0.19–0.64) | 0.34 (0.19–0.61) | 0.0003 |
 Met+glinide users | 55 | 5247 | 105 | 0.94 (0.72–1.23) | 0.83 (0.64–1.09) | 0.18 |
 Met+DPP-4I users | 1 | 194 | 51.7 | 0.55 (0.08–3.94) | 0.53 (0.07–3.77) | 0.52 |
Hemorrhagic stroke | ||||||
 Met+SU users | 303 | 164,609 | 18.4 | Ref. | Ref. | – |
 Met+AGI users | 5 | 3813 | 13.1 | 0.77 (0.32–1.88) | 0.82 (0.34–1.99) | 0.66 |
 Met+TZD users | 2 | 2863 | 6.98 | 0.41 (0.10–1.64) | 0.41 (0.10–1.64) | 0.21 |
 Met+glinide users | 11 | 5378 | 20.5 | 1.16 (0.64–2.12) | 1.08 (0.59–1.98) | 0.80 |
 Met+DPP-4I users | 0 | 194 | 0 | – | – | – |
Mortality | ||||||
 Met+SU users | 2640 | 165,404 | 160 | Ref. | Ref. | – |
 Met+AGI users | 37 | 3824 | 96.8 | 0.78 (0.56–1.08) | 0.83 (0.60–1.15) | 0.26 |
 Met+TZD users | 29 | 2872 | 101 | 0.79 (0.55–1.14) | 0.81 (0.56–1.17) | 0.27 |
 Met+glinide users | 79 | 5392 | 147 | 1.07 (0.86–1.34) | 0.93 (0.74–1.16) | 0.51 |
 Met+DPP-4I users | 1 | 194 | 51.4 | 0.75 (0.11–5.34) | 0.79 (0.11–5.61) | 0.81 |